

AMENDMENTS TO THE CLAIMS

1. (currently amended) A method of inducing an immune response by administration of a recombinant immunogen comprising a fusion protein of an antigen of interest fused to the A2 and B subunits of a type II heat-labile enterotoxin, ~~wherein said immune response is selected from the group consisting of development of antigen-specific T cells in the circulation and tissues, the development of cytotoxic T cells and immunological tolerance to the antigen sequence.~~
2. (original) The method of claim 1, wherein said antigen of interest is salivary binding protein (SBR) from *Streptococcus mutans* surface protein (Ag I/II).
3. (original) The method of claim 1, wherein said type II heat-labile enterotoxin is selected from the group consisting of *E. coli* heat-labile type IIa toxin and *E. coli* heat-labile type IIb toxin.
- 4-5. (canceled)

6. (currently amended) The method of claim 1, wherein said immunogen is administered by a route selected from the group consisting of orally, intranasally, intrarectally, and intravaginally, intramuscularly, transcutaneously and subcutaneously.

7-23. (canceled)

24. (currently amended) A method of increasing Th1 response and cell-mediated immunity by administration of a recombinant immunogen comprising a fusion protein of an antigen of interest fused to the A2 and B subunits of a type II heat-labile enterotoxin.

25. (original) The method of claim 24, wherein said antigen of interest is salivary binding protein (SBR) from *Streptococcus mutans* surface protein (Ag I/II).

26. (original) The method of claim 24, wherein said immunogen is administered by a route selected from the group consisting of orally, intranasally, intrarectally, intravaginally, intramuscularly, transcutaneously and subcutaneously.

27. (currently amended) A method of increasing Th1 response and cell-mediated immunity by administration of a recombinant immunogen comprising a fusion protein of an antigen of interest fused to the A2 and B subunits of a *E. coli* heat-labile type IIa or type IIb toxin.

28. (original) The method of claim 27, wherein said antigen of interest is salivary binding protein (SBR) from *Streptococcus mutans* surface protein (Ag I/II).

29. (original) The method of claim 27, wherein said immunogen is administered by a route selected from the group consisting of orally, intranasally, intrarectally, intravaginally, intramuscularly, transcutaneously and subcutaneously.